Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

MSK researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a ...

Immune cells might be reprogrammed to use the body’s fructose — a naturally occurring sugar — as an energy source that supercharges them to fight cancer, researchers at Memorial Sloan Kettering Cancer ...

Research at MSK Our research impact Research topics Core facilities & resources ...

The Lee laboratory studies the mechanisms governing homeostatic turnover and reparative programs in stem cells, with a focus on elucidating how tissue perturbations lead to lung disease. We ...

Research at MSK Our research impact Research topics Core facilities & resources ...

Our lab develops novel computational methods to study cellular biological systems from a global and data-driven perspective. We seek to exploit diverse, high-throughput functional and genomic data to ...

Thursday, April 3, 2025 - 2:00 p.m. to 3:00 p.m.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial giant cell tumor, based on a trial led by an MSK researcher.

Atomic force microscopy images show hepatitis B DNA in its natural state (left) and a zoomed-in look at how it wraps around human histones during an infection (right). Disrupting this process in an ...